These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30691245)

  • 21. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: a follow-up study.
    Coimbra S; Oliveira H; Belo L; Figueiredo A; Rocha-Pereira P; Santos-Silva A
    Am J Clin Dermatol; 2013 Feb; 14(1):49-53. PubMed ID: 23329079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review of UV-based therapy for psoriasis.
    Almutawa F; Alnomair N; Wang Y; Hamzavi I; Lim HW
    Am J Clin Dermatol; 2013 Apr; 14(2):87-109. PubMed ID: 23572293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantification of histopathological changes in patients with psoriasis before and after phototherapy.
    Noronha-Neta MI; Picciani BLS; Niemeyer-Corbellini JP; Ramos-E-Silva M; Soares FA; Carneiro S
    Photodermatol Photoimmunol Photomed; 2019 Sep; 35(5):354-359. PubMed ID: 31166623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
    Boehncke S; Salgo R; Garbaraviciene J; Beschmann H; Hardt K; Diehl S; Fichtlscherer S; Thaçi D; Boehncke WH
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1187-93. PubMed ID: 21241371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography.
    Dey AK; Joshi AA; Chaturvedi A; Lerman JB; Aberra TM; Rodante JA; Teague HL; Harrington CL; Rivers JP; Chung JH; Kabbany MT; Natarajan B; Silverman JI; Ng Q; Sanda GE; Sorokin AV; Baumer Y; Gerson E; Prussick RB; Ehrlich A; Green LJ; Lockshin BN; Ahlman MA; Playford MP; Gelfand JM; Mehta NN
    JAMA Cardiol; 2017 Sep; 2(9):1013-1018. PubMed ID: 28564678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recovery of the response to biological treatments using narrow band ultraviolet-B in patients with moderate to severe psoriasis: a retrospective study of 17 patients.
    Belinchón I; Arribas MP; Soro P; Betlloch I
    Photodermatol Photoimmunol Photomed; 2014 Dec; 30(6):316-22. PubMed ID: 25132192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum YKL-40 and IL 17 in Psoriasis: Reliability as prognostic markers for disease severity and responsiveness to treatment.
    Khashaba SA; Attwa E; Said N; Ahmed S; Khattab F
    Dermatol Ther; 2021 Jan; 34(1):e14606. PubMed ID: 33249724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: "right-left intra-individual pre/post comparison design".
    Brazzelli V; Barbagallo T; Prestinari F; Rona C; De Silvestri A; Trevisan V; Borroni G
    Int J Immunopathol Pharmacol; 2005; 18(4):755-60. PubMed ID: 16388725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor-alpha-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients.
    Serwin AB; Sokolowska M; Chodynicka B
    Photodermatol Photoimmunol Photomed; 2010 Feb; 26(1):36-40. PubMed ID: 20070837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J
    J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.